OrSense NBM-200 Non-Invasive Hemoglobin Device Selected by the Central Blood Bank of Catalonia
PETACH TIKVA, Israel, July 11, 2019 /PRNewswire/ -- OrSense Ltd., a leading developer of systems for non-invasive measurements of hemoglobin, today announces the selection of its NBM-200 non-invasive Hemoglobin measurement device by the Banc de Sang I Teixits, the central blood bank of Catalonia.
Banc de Sang was one of the first major blood banks in Europe to move from capillary to non-invasive pre-donation hemoglobin testing. It has been running the NBM-200 for over five years, conducting nearly 2 million tests during the period. The new contract is for two years, with three one-year extension options, for a total of five years.
The NBM-200 uses OrSense's proprietary Occlusion Spectroscopy technology to replace traditional invasive blood testing, offering accurate, painless, hemoglobin measurements on location. The non-invasive test further reduces infection risk, as no blood is drawn, and with no consumables, such as lancets, gloves etc. and no need for hazardous waste handling, the system is also environmentally friendly.
The NBM-200 was recently cleared by the FDA's CBER division for use in U.S. blood donation centers.
"We are very happy with the Banc de Sang's decision to select the NBM-200 again," said Yoav Reisman, CEO of OrSense. "The finger stick is often mentioned by donors as the most painful part of the blood donation process. The NBM200's hemoglobin measurement is painless and represents a win/win for blood donors and blood bank organizations; it makes the blood donor experience more comfortable and provides for more efficient, lower cost operations for blood collection centers."
OrSense is a medical device company developing and marketing non-invasive hemoglobin, pulse, and oximetry measurement systems based on its proprietary Occlusion Spectroscopy technology. OrSense's systems have been successfully installed in dozens of blood donation and plasma collection facilities worldwide. More recently, OrSense has begun offering the NBM200 to other professional healthcare market segments, including selected physician clinics and anemia screening locations. For additional information, please visit OrSense's website at www.orsense.com
About The Banc De Sang I Teixits
The Banc de Sang i Teixits (Blood and Tissue Bank, BST) is a public agency of the Catalan Department of Health whose mission is to guarantee the supply and proper use of human blood and tissue in Catalonia. It is also a leading center in the field of immunodiagnostics and advanced therapy development.
OrSense Ltd. contact:
View original content to download multimedia:http://www.prnewswire.com/news-releases/orsense-nbm-200-non-invasive-hemoglobin-device-selected-by-the-central-blood-bank-of-catalonia-300883949.html
SOURCE OrSense Ltd.
Upcoming Life Sciences Events
- September 2019
- Boston: 9th Annual American Drug Delivery & Formulation Summit
- Malmo: NLS Days 2019
- Boston: Redefining Early Stage Investments (RESI)
Latest company news
Janssen Korea Ltd. and Johnson & Johnson Innovation Announce Launch of Seoul Innovation QuickFire Challenge in Smart Healthcare in Collaboration with Seoul Metropolitan Government and Korea Health Industry Development Institute